Another RET inhibitor cabozantinib is effective against a subset of NB cells in vitro by decreasing RET and ERK phosphorylation and cabozantinib inhibits tumor growth in vivo [42], suggesting that targeting RET is a promising treatment strategy in NB. The gene discussed is RET; the disease is neuroblastoma.